2017
DOI: 10.2147/ott.s119362
|View full text |Cite
|
Sign up to set email alerts
|

Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors

Abstract: Nanomedicine application in cancer immunotherapy is currently one of the most challenging areas in cancer therapeutic intervention. Innovative solutions have been provided by nanotechnology to deliver cytotoxic agents to the cancer cells partially affecting the healthy cells of the body during the process. Nanoparticle-based drug delivery is an emerging approach to stimulate the immune responses against cancer. The inhibition of indoleamine 2,3-dioxygenase (IDO) is a pivotal area of research in cancer immunoth… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(13 citation statements)
references
References 139 publications
0
13
0
Order By: Relevance
“…The interference with MSC-mediated immunosuppressive molecular mechanisms, obtained using specific inhibitory drugs, is an additional mean by which the immune escape favored by tumor MSC can be avoided ( 1 4 ). In this context, all the inhibitors already used in therapeutic schemes to block IDO, HO, ARGI and II, NOS2, PGE 2 , and TGF-β activity can be employed to reduce MSC influence on tumor cell growth ( 211 217 ) (Figure 3 ). In this context, the immune check point inhibitors anti-PD1 and/or PDL-1 huAb can have an important role ( 132 , 137 , 218 220 ).…”
Section: Research Gaps and Future Developmentsmentioning
confidence: 99%
“…The interference with MSC-mediated immunosuppressive molecular mechanisms, obtained using specific inhibitory drugs, is an additional mean by which the immune escape favored by tumor MSC can be avoided ( 1 4 ). In this context, all the inhibitors already used in therapeutic schemes to block IDO, HO, ARGI and II, NOS2, PGE 2 , and TGF-β activity can be employed to reduce MSC influence on tumor cell growth ( 211 217 ) (Figure 3 ). In this context, the immune check point inhibitors anti-PD1 and/or PDL-1 huAb can have an important role ( 132 , 137 , 218 220 ).…”
Section: Research Gaps and Future Developmentsmentioning
confidence: 99%
“…Their stability is due to PEG and lipid encapsulation, which can also improve the poor water solubility of loaded Arte (Figure 1A). In addition, PEG, as a surfactant, can form a water barrier on the surface of the phospholipid membrane and prolong the retention time in the blood circulation 2224Figure 2F shows the UV-Vis spectra of FA-ALNBs, which exhibited absorbance peak similar to Arte at wavelengths of 280 nm, demonstrating the existence of Arte in FA-ALNBs.…”
Section: Resultsmentioning
confidence: 99%
“…Bona fide transcription factor binding sites have been detected by ChIP-seq for a large catalog of human transcription factors ( 3 ). The identified gene regulatory proteins involve (i) NF- κB, which allows IDO1 mRNA expression regulation through the interferon pathway ( 6 ), (ii) the aryl hydrocarbon receptor (AhR) that binds to putative dendritic-cell responsive elements and promotes the l -Kyn-dependent induction of IDO1 ( 7 , 8 ), and (iii) CTCF that mediates IDO1 expression via long-range chromatin looping interactions between the promoter and distal enhancer regions ( 9 ).…”
Section: Introductionmentioning
confidence: 99%
“…Indoleamine-2,3-dioxygenase1 production is elevated upon (i) IFN-γ production of effector T cells ( 2 ), (ii) inflammatory cytokine production of innate immune cells ( 6 , 38 ), (iii) IL-10 and IL-27 stimulation ( 39 ), (iv) CTLA4 expression on Treg cells causing increased IDO1 secretion by dendritic cells (DCs) ( 40 ), and (v) TGF-β, IL-10 and adenosine production of Treg and other immunosuppressive cells ( 40 42 ), (vi) cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) stimuli that are mediated through the PKC, PI3K, and MAPK pathways (several types of tumors carry PI3K or MAPK oncogenic mutations leading to constitutive IDO1 expression.) ( 43 ).…”
Section: Introductionmentioning
confidence: 99%